Effect of Statin Adherence on Cerebrovascular Disease in Primary Prevention

American Journal of Medicine

Volumn 122, Issue 7, 2009, Pages 647-655

  Perreault, Sylvie ^a   Ellia, Laura ^a   Dragomir, Alice ^a   Côté, Robert ^b   Blais, Lucie ^a   Bérard, Anick ^a   Lalonde, Lyne ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Adherence; Cerebrovascular disease; Observational study; Statins

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ADULT; AGED; ARTICLE; CEREBROVASCULAR DISEASE; CONTROLLED STUDY; DIABETES MELLITUS; EMERGENCY CARE; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PATIENT COMPLIANCE; PRIMARY PREVENTION; PRIORITY JOURNAL; RISK FACTOR; RISK REDUCTION;

AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CEREBROVASCULAR DISORDERS; COHORT STUDIES; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PRIMARY PREVENTION;

EID: 67649845822     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2009.01.032     Document Type: Article

References (45)

1. Goldstein L.B., Adams R., Alberts M.J., et al. Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council: cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: the American Academy of Neurology affirms the value of this guideline. Stroke 37 (2006) 1583-1633
2. Heart and Stroke Foundation of Canada. The Growing Burden of Heart Disease and Stroke in Canada, 2003 (2003), Heart and Stroke Foundation of Canada, Ottawa, Canada
3. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344 (1994) 1383-1389
4. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360 (2002) 7-22
5. Sever P.S., Poulter N.R., Dahlöf B., and Wedel H. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361 (2003) 1149-1158
6. Colhoum H.M., Betteridge D.J., Durrington P.N., et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364 (2004) 685-696
7. Shepherd J., Blauw G.J., Murphy M.B., et al., PROSPER study group. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360 (2002) 1623-1630
8. Shepherd J., Cobbe S.M., Ford I., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 333 (1995) 1301-1308
9. Downs J.R., Clearfield M., Weis S., et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279 (1998) 1615-1622
10. Larosa J.C., Grundy A.M., Waters D.D., et al., Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352 (2005) 1425-1435
11. Briel M., Studer M., Glass T.R., and Bucher H.C. Effects of statins on stroke prevention in patients with and without coronary heart disease: a meta-analysis of randomized controlled trials. Am J Med 117 (2004) 596-606
12. Thavendiranathan P., Bagai A., Brookhart M.A., and Choudhry N.K. Primary prevention of cardiovascular diseases with statin therapy: a meta-analysis of randomized controlled trials. Arch Intern Med 166 (2006) 2307-2313
13. O'Regan C., Wu P., Arora P., Perri D., and Mills E.J. Statin therapy in stroke prevention: a meta-analysis involving 121,000 patients. Am J Med 121 (2008) 24-33
14. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomized trials of statin. Lancet 366 (2005) 1267-1278
15. Collins R., Armitage J., Parish S., et al. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20,536 people with cerebrovascular disease or other high-risk conditions. Lancet 363 (2004) 757-767
16. Amarenco P., Labreuche J., Lavallée Philippa, and Touboul P.J. Statin in stroke prevention and carotic atherosclerosis. Systematic review and up-to-date meta-analysis. Lancet 356 (2004) 2902-2909
17. Benner J.S., Glynn R.J., Mogun H., et al. Long-term persistence in use of statin therapy in elderly patients. JAMA 288 (2002) 455-461
18. Perreault S., Blais L., Lamarre D., et al. Persistence and determinants of statin therapy among middle-aged patients for primary and secondary prevention. Br J Clin Pharmacol 59 (2005) 564-573
19. International Classification of Diseases. Manual of the International Statistical Classification of Diseases, Injuries, and Cause of Death. 9th edn. (1977), World Health Organization, Geneva, Switzerland Publication no PHS 80-1260
20. Minister of Supply and Services Canada. Canadian Classification of Diagnostic, Therapeutic, and Surgical Procedures. 2nd edn. (1986), Statistics Canada Health Division, Ottawa, Ontario, Canada
21. Régie d'assurance maladie du Québec. Principales variables selon la catégorie de personnes assures [French]. Studies and Statistics 2005. http://www.ramq.gouv.qc.ca Accessed September 20, 2006
22. Tamblyn R., Lavoie G., Petrella L., and Monette J. The use of prescription claims databases in pharmacoepidemiological research: the accuracy and comprehensiveness of the prescription claims database in Quebec. J Clin Epidemiol 48 (1995) 999-1009
23. Wilchesky M., Tamblyn R., and Huang A. Validation of diagnostic codes within medical services claims. J Clin Epidemiol 57 (2004) 131-141
24. Tirschwell D.L., and Longstreth W.T. Validating administrative data in stroke research. Stroke 33 (2002) 2465-2470
25. Ernster V.L. Nested case-control studies. Prev Med 23 (1994) 587-590
26. Essebag V., Genest J., Suissa S., and Pilote L. The nested case-control study in cardiology. Am Heart J 146 (2003) 581-590
27. Sikka R., Xia F., and Aubert R.E. Estimating medication persistency using administrative claims data. Am J Manag Care 11 (2005) 449-457
28. LaRosa J.C., He J., and Vupputuri S. Effect of statins risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA 282 (1999) 2340-2346
29. Kendrach M., and Kelly-Freeman M. Approximate equivalent rosuvastatin doses for temporary statin interchange programs. Ann Pharmacother 38 (2004) 1286-1292
30. Jones P., Kafonet S., Laurora I., and Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia. Am J Cardiol 81 (1998) 582-587
31. Von Korff M., Wagner E.H., and Saunders K. A chronic disease score from automated pharmacy data. J Clin Epidemiol 45 (1992) 197-203
32. Essebag V., Platt R., Abrahamowicz M., and Pilote L. Comparison of nested case-control and survival analysis methodologies for analysis of time-dependent exposure. BMC Med Res Method 5 (2005) 5-11
33. Greenland S. Sensitivity analysis, Monte Carlo risk analysis, and Bayesian uncertainty assessment. Risk Anal 21 (2001) 579-583
34. Steenland K., and Greenland S. Monte Carlo sensitivity analysis and Bayesian analysis of smoking as an unmeasured confounder in a study of silica and lung cancer. Am J Epidemiol 160 (2004) 384-392
35. Greene W.H. Econometric Analysis. 3rd edn. (1997), Prentice-Hall, Upper Saddle River, NJ
36. Belsley D.A., Kuy E., and Welsch R.E. Regression Diagnostics: Identifying Influential Data and Sources of Collinearity (1981), John Wiley & Sons, New York
37. Ridker P.M., Rifai N., Pfeffer M.A., et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation 98 (1998) 839-844
38. Ridker P.M., Rifai N., Clearfield M., et al., Air Force/Texas Coronary Atherosclerosis Prevention Study Investigators. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 344 (2001) 1959-1965
39. Crisby M., Nordin-Fredriksson G., Shah P.K., et al. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation 103 (2001) 926-933
40. Levine G.N., Keaney Jr. J.F., and Vita J.A. Cholesterol reduction in cardiovascular disease: clinical benefits and possible mechanisms. N Engl J Med 332 (1995) 512-521
41. Rosenson R.S., and Tangney C.C. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA 279 (1998) 1643-1650
42. Takemoto M., and Liao J.K. Pleiotrophic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arterioscler Thromb Vasc Biol 21 (2001) 1712-1719
43. Osterberg L., and Blaschke T. Adherence to medication. N Engl J Med 353 (2005) 487-497
44. Sacco R.L., Benjamin E.J., Broderick J.P., et al. Risk factors. Stroke 28 (1997) 1507-1517
45. Kim Y.S., Sunwoo S., Lee H.R., et al., Korea Post-Marketing Surveillance Research Group. Determinants of non-compliance with lipid-lowering therapy in hyperlipidemic patients. Pharmacoepidemiol Drug Saf 11 (2002) 593-600